金凯生科：2025年净利同比预增138.28%-200.45%

Core Viewpoint - KingKaiser Biotechnology (301509.SZ) forecasts a net profit attributable to shareholders of 92 million to 116 million yuan for the year 2025, representing a year-on-year growth of 138.28% to 200.45% [1] Group 1 - The increase in net profit is attributed to a recovery in end-user demand and the delivery schedule of customer orders, leading to an increase in order deliveries during the reporting period [1] - The overall gross profit margin improved due to the impact of the product mix of delivered orders [1] - These combined factors resulted in a significant year-on-year increase in the company's performance for 2025 [1]